Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effectiveness, Safety and Tolerability of RP-G28 in Subjects With Symptoms Associated With Lactose Intolerance
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2017
Price : $35 *
At a glance
- Drugs RP G28 (Primary)
- Indications Lactose intolerance
- Focus First in man; Proof of concept; Therapeutic Use
- Sponsors Ritter Pharmaceuticals
- 03 Jan 2017 According to a Ritter Pharmaceuticals media release, data from this trial published in Nutrition Journal Article 2013.
- 03 Jan 2017 Results published in the Ritter Pharmaceuticals Media Release
- 03 Jan 2017 According to a Ritter Pharmaceuticals media release, data from this trial published in the Proceedings of the National Academy of Science ("PNAS-Plus") PNAS 2017; Early Edition.